Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease

NCT01621178 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01621178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01621178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2012
Completion date
December 31, 2016
Enrollment
577 (actual)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, type 2 diabetes